-------- Original Version -----------
Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD-------- English Version ------------
Press Release: ATS: Phase 2 Data Demonstrate Efdoralprin Alfa's Superiority Over Standard-of-Care Augmentation Therapy in Achieving Higher FAIAT Levels in AATD-------- Link if available ----------